コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the blood-brain-barrier (BBB) and eliminates systemic side effects.
2 g expansion of aneurysms in patients without systemic side effects.
3 patient tolerance and no noticeable local or systemic side effects.
4 to control/eradicate HIV as well as mitigate systemic side effects.
5 se in situ efficacy of the drug and minimize systemic side effects.
6 unds drives myocardial contractility without systemic side effects.
7 lity of drug and the potential for local and systemic side effects.
8 sia restored rcSO2 to control levels with no systemic side effects.
9 igh efficacy, low operative morbidity and no systemic side effects.
10 cations, including multiorgan toxicities and systemic side effects.
11 than SLIT alone but was accompanied by more systemic side effects.
12 es and may allow reduced systemic dosage and systemic side effects.
13 compound alone was directly associated with systemic side effects.
14 ral ischemia-related injury while minimizing systemic side effects.
15 ote long-term engraftment without associated systemic side effects.
16 ied counterparts, due to the reduced rate of systemic side effects.
17 also be expected to reduce the potential for systemic side effects.
18 in a dose-related, reversible manner without systemic side effects.
19 rugs and they are associated with ocular and systemic side effects.
20 fects to the lung vasculature, thus avoiding systemic side effects.
21 ment of myopia, but has undesired ocular and systemic side effects.
22 zer; however, its clinical use is limited by systemic side effects.
23 ed clinical trials because of their unwanted systemic side effects.
24 and colon carcinoma without any significant systemic side effects.
25 may be of benefit although at the expense of systemic side effects.
26 necessary, without any significant local or systemic side effects.
27 strategies without significant drug-specific systemic side effects.
28 immunosuppressive options are limited due to systemic side effects.
29 metastatic liver cancer, without increasing systemic side effects.
30 improve cardiac function but are limited by systemic side effects.
31 orbed into the bloodstream, which results in systemic side effects and a brief residence time in the
32 press the immune system in order to minimize systemic side effects and deliver sufficient nanoparticl
33 ential to significantly decrease undesirable systemic side effects and reduce required therapeutic do
34 is associated with local and, in some cases, systemic side effects and suffers from low patient compl
36 ness and itching) but a similar incidence of systemic side effects and was preferred by study partici
37 he transplanted allograft, which would limit systemic side effects, and prolong allograft survival.
40 he immune system, coupled with the potential systemic side effects associated with traditional system
41 ectly to the site of inflammation and avoids systemic side effects but often fails to modulate system
42 tments for many CNS diseases, while reducing systemic side effects by providing sustained, well-dispe
43 e, it seems reasonable to classify and grade systemic side effects by using the previously published
44 to 7 years with no evident increased risk of systemic side effects compared with regional corticoster
45 vascular endothelial cells, cytotoxicity and systemic side effects dampen enthusiasm for their use in
46 cally, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology.
47 however, can be associated with significant systemic side effects due to the drugs' lack of tissue s
48 ept in strict isolation to monitor local and systemic side-effects, environmental spread, and anti-E6
49 atient tolerance is often poor due to common systemic side effects following oral administration.
51 of action than the B serotype and has fewer systemic side effects; hence, it is more likely to gain
56 en considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and loca
59 is is impaired by poor drug bioavailability, systemic side effects, patient non-compliance, and patho
61 uximab, lapatinib, and panitumumab have less systemic side-effects than traditional cytotoxic chemoth
62 are an APOE4-specific AD therapeutic and the systemic side effects that limit translational applicati
64 compromising the immune system or eliciting systemic side effects, we investigated the use of T-bet-
69 lfoxide (DMSO), which can cause a variety of systemic side effects when the graft is thawed and infus
71 icant increase in the incidence of local and systemic side effects, which was felt to outweigh the sm
72 caused any detectable epithelial toxicity or systemic side effects with very low drug levels measured
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。